Analgesics Market Report 2026

The analgesics market size has grown steadily in recent years. It will grow from $113.1 billion in 2025 to $115.82 billion in 2026 at a compound annual growth rate (CAGR) of 2.4%. The growth in the historic period can be attributed to rise in global musculoskeletal disorders, increase in surgical procedures, growing cancer incidence, expansion of hospital infrastructure, widespread availability of generic analgesics.

The analgesics market size is expected to see steady growth in the next few years. It will grow to $132.6 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to advancements in personalized medicine, increased r&d in opioid alternatives, growth of e-pharmacies and digital healthcare, rising geriatric population, adoption of smart manufacturing in pharma. Major trends in the forecast period include personalized pain management solutions, growth in opioid and non-opioid drug development, expansion of hospital and retail pharmacy channels, increase in chronic pain and cancer pain treatment demand, rising awareness of safe analgesic usage.

The rise in healthcare expenditures is expected to drive the growth of the analgesics market. Healthcare expenditures encompass costs for providing medical services, family planning, nutrition programs, and emergency care. Increased spending fuels research and development in the pharmaceutical sector, supporting the development of new and improved analgesic drugs. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% nominal increase in total healthcare spending from 2022 to 2023. Therefore, rising healthcare expenditures are propelling the analgesics market.

Key companies in the analgesics market are focusing on combination analgesics to enhance efficacy and competitiveness. Combination analgesics include two or more pain-relieving drugs, targeting pain through multiple mechanisms for superior relief. For example, in February 2024, Hikma Pharmaceuticals plc, a UK-based company, launched COMBOGESIC IV (acetaminophen and ibuprofen) in the US. This intravenous formulation combines 1,000 mg of acetaminophen and 300 mg of ibuprofen, providing dual-action pain relief with faster onset and improved safety as a non-opioid alternative.

In December 2023, Wellnex Life Limited, an Australian health and wellness company, acquired Pain Away Ltd. for $22 million. This acquisition strengthens Wellnex’s presence in defensive healthcare, expanding its portfolio with topical pain relief products. Pain Away Ltd. is a US-based company specializing in the development and distribution of topical analgesics.

Major companies operating in the analgesics market are Pfizer Inc., Johnson & Johnson Services Inc., Medley Pharmaceuticals Limited, AbbVie Inc., Bayer HealthCare Pharmaceuticals LLC, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca Plc., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical company Limited, Eli Lilly and Company, Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Limited, Purdue Pharma L.P, Cipla Limited, Allergan Inc., Endo International plc, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals Ltd., Chattem Inc., Hisamitsu Pharmaceutical Co.Inc., GW Pharmaceuticals, Verve Health Care Ltd., Alder BioPharmaceuticals Inc., Achelios Therapeutics Inc., WEX Pharmaceuticals Inc., Zynerba Pharmaceuticals, McNeil Consumer & Specialty Medical Products, Innovative Med Concepts LLC.

North America was the largest region in the analgesics market in 2025. Middle East is expected to be the fastest-growing region in the global analgesics market during the forecast period. The regions covered in the analgesics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the analgesics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the analgesics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials, particularly impacting opioid and non-opioid drug segments. Regions like North America and Europe, which rely on imports from Asia-Pacific manufacturing hubs such as China and India, face higher production costs and supply chain delays. Hospital and retail pharmacy channels are most affected due to price sensitivity and regulatory compliance challenges. However, tariffs have also incentivized local manufacturing and supply diversification, potentially boosting domestic production capacities in the long term.

The analgesics market research report is one of a series of new reports that provides analgesics market statistics, including analgesics industry global market size, regional shares, competitors with a analgesics market share, detailed analgesics market segments, market trends and opportunities, and any further data you may need to thrive in the analgesics industry. This analgesics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Analgesics are pain-relieving medications used to manage mild to severe pain, including musculoskeletal pain, surgical or trauma-related pain, cancer pain, and other types of pain. Examples include codeine, hydrocodone, oxycodone, and methadone.

The main types of analgesics are non-opioids and opioids. Non-opioid analgesics are available over-the-counter (OTC) or by prescription and are increasingly used as a safe and effective first-line option for mild to severe acute and chronic pain in various clinical settings. Analgesics include prescription and OTC drugs and can be administered orally, intravenously, rectally, transdermally, or topically. They are used as internal and external analgesics and are distributed through hospital pharmacies, retail pharmacies, and drug stores.

The analgesics market consists of sales of codeine, hydrocodone, oxycodone, and methadone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.